Finerenone Efficacy and Safety in Patients with Chronic Kidney Disease and Glomerular Disease
Finerenone slows kidney function loss in patients with glomerular disease
Finerenone significantly slows eGFR decline and reduces albuminuria in patients with glomerular disease, offering a new therapeutic option f…
A new clinical trial shows that the medication finerenone helps slow kidney decline and reduces protein in the urine for people with specifi…
Unified cardiometabolic disease framework links T2DM, ASCVD, HFpEF, MASLD, hypertension, and CKD via shared pathophysiology
New Framework Links Heart and Kidney Health in Diabetes
This guideline provides a narrative review of the unified cardiometabolic disease (UCD) continuum. It argues that conditions like T2DM, ASCV…
Experts suggest that diabetes, heart failure, and kidney disease may share a single underlying cause rather than being separate conditions.
Finerenone reduces mortality and heart failure risk (HR 0.644) in post-AMI patients
Finerenone may lower heart failure risk after heart attack
This retrospective cohort study of 1,012 adult patients with AMI found that finerenone initiation within 6 months was associated with a lowe…
A new look at real-world data suggests the drug finerenone could protect hearts and kidneys in patients following a heart attack.
Finerenone reduces composite cardiovascular death and worsening heart failure events in patients with symptomatic heart failure
Finerenone Reduces Heart Failure Events in Specific Patient Groups
This narrative review evaluates finerenone for patients with symptomatic heart failure and LVEF ≥40%. It finds that finerenone reduces the c…
A new medication called finerenone may help reduce certain heart failure events for adults with specific types of heart muscle function.
Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction
This network meta-analysis evaluated finerenone, sodium–glucose cotransporter 2 inhibitors, renin–angiotensin system inhibitors, and angiote…
A large review of over 65,000 patients found that finerenone and SGLT2 inhibitors reduce hospital stays and worsening heart failure compared…
Combining finerenone with SGLT2 inhibitors lowers mortality and cardiovascular events in diabetic chronic kidney disease patients
A Two-Drug Combo May Save Lives in Diabetic Kidney Disease
A meta-analysis of 1,580 patients shows dual therapy with finerenone and SGLT2 inhibitors significantly reduces mortality and kidney events …
A new analysis finds that pairing finerenone with an SGLT2 inhibitor may significantly lower the risk of death and heart problems for people…
Systematic review and meta-analysis of MRAs in dialysis patients shows reduced nonfatal CVD events but elevated hyperkalemia and gynecomastia risks
New analysis shows dialysis drugs cut heart attacks but raise dangerous potassium risks
This systematic review and meta-analysis evaluated mineralocorticoid receptor antagonists (MRAs) in adults on maintenance dialysis.
A large review of dialysis patients found that specific heart drugs reduced nonfatal heart events but increased risks of severe potassium bu…
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients
Does finerenone help kidney risk categories improve in diabetes patients compared to placebo?
A post hoc subanalysis of an RCT in patients with type 2 diabetes and chronic kidney disease found finerenone therapy was associated with a …
Patients with diabetes and kidney disease taking finerenone were much more likely to see their kidney risk category improve and less likely …